(Q36661867)

15 August 2017

1 reference

title

Urgent inhibitor issues: targets for expanded research (English)

1 reference

15 August 2017

Hoots WK

1

1 reference

15 August 2017

publication date

1 December 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

12 Suppl 6

1 reference

15 August 2017

page(s)

107-113

1 reference

Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs?

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01374.X

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01374.X

A longitudinal study of serum beta 2-microglobulin levels in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01374.X

Effect of factor VIII concentrate on leucocyte cytokine receptor expression in vitro: relevance to inhibitor formation and tolerance induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01374.X

Induction of tolerance to human factor VIII in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01374.X

Oral immune tolerance induction to factor VIII via breast milk, a possibility?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01374.X

Is oral tolerance therapy possible for haemophilia with inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01374.X

Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01374.X

Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01374.X

International immune tolerance registry, 1997 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01374.X

Rituximab in the treatment of acquired factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01374.X

Recombinant clotting factors: a review of current clinical status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01374.X

Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01374.X

A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01374.X

10.1111/J.1365-2516.2006.01374.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference